Please use this identifier to cite or link to this item:
標題: H7亞型流感病毒重組HA似病毒顆粒疫苗的免疫效果分析
Immunogenicity and Efficacy of Baculovirus Expressing Recombinant H7 Subtypic Influenza HA Virus-like Particles
作者: 張若麟
Chang, Ro-Lin
關鍵字: influenza virus;流感病毒;virus-like particles;hemagglutinin;vaccine.;似病毒顆粒;血球凝集素;疫苗
出版社: 生物科技學研究所
引用: 參考文獻 1. 1980. Antigenic shift and drift. Nature 283:524-5. 2. Allison, A. G., and G. Gregoriadis. 1974. Liposomes as immunological adjuvants. Nature 252:252. 3. Ambrosch, F., G. Wiedermann, S. Jonas, B. Althaus, B. Finkel, R. Gluck, and C. Herzog. 1997. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 15:1209-13. 4. Arzt, S., I. Petit, W. P. Burmeister, R. W. Ruigrok, and F. Baudin. 2004. Structure of a knockout mutant of influenza virus M1 protein that has altered activities in membrane binding, oligomerisation and binding to NEP (NS2). Virus Res 99:115-9. 5. Baigent, S. J., and J. W. McCauley. 2003. Influenza type A in humans, mammals and birds: determinants of virus virulence, host-range and interspecies transmission. Bioessays 25:657-71. 6. Bangham, A. D., M. M. Standish, and N. Miller. 1965. Cation permeability of phospholipid model membranes: effect of narcotics. Nature 208:1295-7. 7. Baumert, T. F., S. Ito, D. T. Wong, and T. J. Liang. 1998. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J Virol 72:3827-36. 8. Bavari, S., C. M. Bosio, E. Wiegand, G. Ruthel, A. B. Will, T. W. Geisbert, M. Hevey, C. Schmaljohn, A. Schmaljohn, and M. J. Aman. 2002. Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med 195:593-602. 9. Bikram, M., and J. L. West. 2008. Thermo-responsive systems for controlled drug delivery. Expert Opin Drug Deliv 5:1077-91. 10. Blaas, D., E. Patzelt, and E. Kuechler. 1982. Identification of the cap binding protein of influenza virus. Nucleic Acids Res 10:4803-12. 11. Braam, J., I. Ulmanen, and R. M. Krug. 1983. Molecular model of a eucaryotic transcription complex: functions and movements of influenza P proteins during capped RNA-primed transcription. Cell 34:609-18. 12. Bright, R. A., D. M. Carter, S. Daniluk, F. R. Toapanta, A. Ahmad, V. Gavrilov, M. Massare, P. Pushko, N. Mytle, T. Rowe, G. Smith, and T. M. Ross. 2007. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25:3871-8. 13. Brown, C. S., J. W. Van Lent, J. M. Vlak, and W. J. Spaan. 1991. Assembly of empty capsids by using baculovirus recombinants expressing human parvovirus B19 structural proteins. J Virol 65:2702-6. 14. Bui, M., G. Whittaker, and A. Helenius. 1996. Effect of M1 protein and low pH on nuclear transport of influenza virus ribonucleoproteins. J Virol 70:8391-401. 15. Chen, B. J., G. P. Leser, E. Morita, and R. A. Lamb. 2007. Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J Virol 81:7111-23. 16. Cheung, T. K., and L. L. Poon. 2007. Biology of influenza a virus. Ann N Y Acad Sci 1102:1-25. 17. Copeland, C. S., R. W. Doms, E. M. Bolzau, R. G. Webster, and A. Helenius. 1986. Assembly of influenza hemagglutinin trimers and its role in intracellular transport. J Cell Biol 103:1179-91. 18. Crawford, J., B. Wilkinson, A. Vosnesensky, G. Smith, M. Garcia, H. Stone, and M. L. Perdue. 1999. Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes. Vaccine 17:2265-74. 19. de la Luna, S., C. Martinez, and J. Ortin. 1989. Molecular cloning and sequencing of influenza virus A/Victoria/3/75 polymerase genes: sequence evolution and prediction of possible functional domains. Virus Res 13:143-55. 20. de Wit, E., M. I. Spronken, G. Vervaet, G. F. Rimmelzwaan, A. D. Osterhaus, and R. A. Fouchier. 2007. A reverse-genetics system for Influenza A virus using T7 RNA polymerase. J Gen Virol 88:1281-7. 21. Delchambre, M., D. Gheysen, D. Thines, C. Thiriart, E. Jacobs, E. Verdin, M. Horth, A. Burny, and F. Bex. 1989. The GAG precursor of simian immunodeficiency virus assembles into virus-like particles. Embo J 8:2653-60. 22. Deol, P., and G. K. Khuller. 1997. Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim Biophys Acta 1334:161-72. 23. Dileo, J., R. Banerjee, M. Whitmore, J. V. Nayak, L. D. Falo, Jr., and L. Huang. 2003. Lipid-protamine-DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses. Mol Ther 7:640-8. 24. Du, L., G. Zhao, X. Zhang, Z. Liu, H. Yu, B. J. Zheng, Y. Zhou, and S. Jiang. Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies. Biochem Biophys Res Commun. 25. Dzau, V. J., M. J. Mann, R. Morishita, and Y. Kaneda. 1996. Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc Natl Acad Sci U S A 93:11421-5. 26. Enami, M., and K. Enami. 1996. Influenza virus hemagglutinin and neuraminidase glycoproteins stimulate the membrane association of the matrix protein. J Virol 70:6653-7. 27. Felgner, P. L., T. R. Gadek, M. Holm, R. Roman, H. W. Chan, M. Wenz, J. P. Northrop, G. M. Ringold, and M. Danielsen. 1987. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci U S A 84:7413-7. 28. Fernandez-Arias, A., C. Risco, S. Martinez, J. P. Albar, and J. F. Rodriguez. 1998. Expression of ORF A1 of infectious bursal disease virus results in the formation of virus-like particles. J Gen Virol 79 ( Pt 5):1047-54. 29. Fortes, P., A. Beloso, and J. Ortin. 1994. Influenza virus NS1 protein inhibits pre-mRNA splicing and blocks mRNA nucleocytoplasmic transport. Embo J 13:704-12. 30. Fortin, A., E. Shahum, K. Krzystyniak, and H. M. Therien. 1996. Differential activation of cell-mediated immune functions by encapsulated and surface-linked liposomal antigens. Cell Immunol 169:208-17. 31. Fouchier, R. A., V. Munster, A. Wallensten, T. M. Bestebroer, S. Herfst, D. Smith, G. F. Rimmelzwaan, B. Olsen, and A. D. Osterhaus. 2005. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol 79:2814-22. 32. French, T. J., J. J. Marshall, and P. Roy. 1990. Assembly of double-shelled, viruslike particles of bluetongue virus by the simultaneous expression of four structural proteins. J Virol 64:5695-700. 33. Friedrichson, T., and T. V. Kurzchalia. 1998. Microdomains of GPI-anchored proteins in living cells revealed by crosslinking. Nature 394:802-5. 34. Galarza, J. M., T. Latham, and A. Cupo. 2005. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 18:244-51. 35. Gamblin, S. J., and J. J. Skehel. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem 285:28403-9. 36. Gao, Q., A. C. Lowen, T. T. Wang, and P. Palese. A nine-segment influenza a virus carrying subtype H1 and H3 hemagglutinins. J Virol 84:8062-71. 37. Gomez-Puertas, P., C. Albo, E. Perez-Pastrana, A. Vivo, and A. Portela. 2000. Influenza virus matrix protein is the major driving force in virus budding. J Virol 74:11538-47. 38. Greenspan, D., P. Palese, and M. Krystal. 1988. Two nuclear location signals in the influenza virus NS1 nonstructural protein. J Virol 62:3020-6. 39. Guan, H. H., W. Budzynski, R. R. Koganty, M. J. Krantz, M. A. Reddish, J. A. Rogers, B. M. Longenecker, and J. Samuel. 1998. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses. Bioconjug Chem 9:451-8. 40. Guerriero, C. J., Y. Lai, and O. A. Weisz. 2008. Differential sorting and Golgi export requirements for raft-associated and raft-independent apical proteins along the biosynthetic pathway. J Biol Chem 283:18040-7. 41. Hampson, A. W., and J. S. Mackenzie. 2006. The influenza viruses. Med J Aust 185:S39-43. 42. Harder, T., P. Scheiffele, P. Verkade, and K. Simons. 1998. Lipid domain structure of the plasma membrane revealed by patching of membrane components. J Cell Biol 141:929-42. 43. Hatta, M., P. Gao, P. Halfmann, and Y. Kawaoka. 2001. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 293:1840-2. 44. Haynes, J. R., L. Dokken, J. A. Wiley, A. G. Cawthon, J. Bigger, A. G. Harmsen, and C. Richardson. 2009. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine 27:530-41. 45. Hebert, D. N., J. X. Zhang, W. Chen, B. Foellmer, and A. Helenius. 1997. The number and location of glycans on influenza hemagglutinin determine folding and association with calnexin and calreticulin. J Cell Biol 139:613-23. 46. Holsinger, L. J., and R. A. Lamb. 1991. Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. Virology 183:32-43. 47. Huang, T. S., P. Palese, and M. Krystal. 1990. Determination of influenza virus proteins required for genome replication. J Virol 64:5669-73. 48. Hutchinson, E. C., J. C. von Kirchbach, J. R. Gog, and P. Digard. Genome packaging in influenza A virus. J Gen Virol 91:313-28. 49. Isaka, Y., Y. Akagi, Y. Ando, M. Tsujie, T. Sudo, N. Ohno, W. A. Border, N. A. Noble, Y. Kaneda, M. Hori, and E. Imai. 1999. Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 55:465-75. 50. Ito, K., and Y. Akiyama. 2005. Cellular functions, mechanism of action, and regulation of FtsH protease. Annu Rev Microbiol 59:211-31. 51. Ito, K., J. Chen, T. Asano, E. D. Vaughan, Jr., D. P. Poppas, M. Hayakawa, and D. Felsen. 2004. Liposome-mediated gene therapy in the kidney. Hum Cell 17:17-28. 52. Ito, K., J. Chen, J. J. Khodadadian, S. V. Seshan, C. Eaton, X. Zhao, E. D. Vaughan, Jr., M. Lipkowitz, D. P. Poppas, and D. Felsen. 2004. Liposome-mediated transfer of nitric oxide synthase gene improves renal function in ureteral obstruction in rats. Kidney Int 66:1365-75. 53. Johansson, B. E. 1999. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine. Vaccine 17:2073-80. 54. Johnson, M. C., H. M. Scobie, and V. M. Vogt. 2001. PR domain of rous sarcoma virus Gag causes an assembly/budding defect in insect cells. J Virol 75:4407-12. 55. Kang, S. M., P. Pushko, R. A. Bright, G. Smith, and R. W. Compans. 2009. Influenza virus-like particles as pandemic vaccines. Curr Top Microbiol Immunol 333:269-89. 56. Kirnbauer, R., F. Booy, N. Cheng, D. R. Lowy, and J. T. Schiller. 1992. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 89:12180-4. 57. Korepanova, A., F. P. Gao, Y. Hua, H. Qin, R. K. Nakamoto, and T. A. Cross. 2005. Cloning and expression of multiple integral membrane proteins from Mycobacterium tuberculosis in Escherichia coli. Protein Sci 14:148-58. 58. Krammer, F., T. Schinko, D. Palmberger, C. Tauer, P. Messner, and R. Grabherr. Trichoplusia ni cells (High Five) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines. Mol Biotechnol 45:226-34. 59. Kretzschmar, E., M. Veit, S. Brunschon, K. Kuroda, and H. D. Klenk. 1992. Secretion of fowl plague virus haemagglutinin from insect cells requires elimination of both hydrophobic domains. J Gen Virol 73 ( Pt 4):839-48. 60. Kwak, L. W., R. Pennington, L. Boni, A. C. Ochoa, R. J. Robb, and M. C. Popescu. 1998. Liposomal formulation of a self lymphoma antigen induces potent protective antitumor immunity. J Immunol 160:3637-41. 61. Lachman, L. B., B. Ozpolat, and X. M. Rao. 1996. Cytokine-containing liposomes as vaccine adjuvants. Eur Cytokine Netw 7:693-8. 62. Lai, L. W., D. M. Chan, R. P. Erickson, S. J. Hsu, and Y. H. Lien. 1998. Correction of renal tubular acidosis in carbonic anhydrase II-deficient mice with gene therapy. J Clin Invest 101:1320-5. 63. Lakey, D. L., J. J. Treanor, R. F. Betts, G. E. Smith, J. Thompson, E. Sannella, G. Reed, B. E. Wilkinson, and P. F. Wright. 1996. Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J Infect Dis 174:838-41. 64. Lanford, R. E., V. Luckow, R. C. Kennedy, G. R. Dreesman, L. Notvall, and M. D. Summers. 1989. Expression and characterization of hepatitis B virus surface antigen polypeptides in insect cells with a baculovirus expression system. J Virol 63:1549-57. 65. Laver, W. G., P. M. Colman, R. G. Webster, V. S. Hinshaw, and G. M. Air. 1984. Influenza virus neuraminidase with hemagglutinin activity. Virology 137:314-23. 66. Li, T. C., Y. Yamakawa, K. Suzuki, M. Tatsumi, M. A. Razak, T. Uchida, N. Takeda, and T. Miyamura. 1997. Expression and self-assembly of empty virus-like particles of hepatitis E virus. J Virol 71:7207-13. 67. Lipowsky, R. 1993. Domain-induced budding of fluid membranes. Biophys J 64:1133-1138. 68. Luo, L., Y. Li, and C. Y. Kang. 1990. Expression of gag precursor protein and secretion of virus-like gag particles of HIV-2 from recombinant baculovirus-infected insect cells. Virology 179:874-80. 69. Macdonald, J. L., and L. J. Pike. 2005. A simplified method for the preparation of detergent-free lipid rafts. J Lipid Res 46:1061-7. 70. Maeshima, Y., N. Kashihara, T. Yasuda, H. Sugiyama, T. Sekikawa, K. Okamoto, K. Kanao, Y. Watanabe, Y. S. Kanwar, and H. Makino. 1998. Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo. J Clin Invest 101:2589-97. 71. Manie, S. N., S. de Breyne, S. Vincent, and D. Gerlier. 2000. Measles virus structural components are enriched into lipid raft microdomains: a potential cellular location for virus assembly. J Virol 74:305-11. 72. Morikawa, S., T. F. Booth, and D. H. Bishop. 1991. Analyses of the requirements for the synthesis of virus-like particles by feline immunodeficiency virus gag using baculovirus vectors. Virology 183:288-97. 73. Mukaigawa, J., and D. P. Nayak. 1991. Two signals mediate nuclear localization of influenza virus (A/WSN/33) polymerase basic protein 2. J Virol 65:245-53. 74. Naito, S., A. Horino, M. Nakayama, Y. Nakano, T. Nagai, J. Mizuguchi, K. Komuro, and T. Uchida. 1996. Ovalbumin-liposome conjugate induces IgG but not IgE antibody production. Int Arch Allergy Immunol 109:223-8. 75. Naito, S., M. Taneichi, H. Kato, Y. Tanaka, Y. Ami, Y. Suzaki, M. Mori, Y. Nakano, H. Yamamura, K. Morokuma, K. Ohkuma, H. Miyake, M. Kiniwa, K. Komuro, and T. Uchida. 2002. Selective inhibition of systemic anti-OVA IgE production in response to oral pre-treatment with OVA-liposome conjugates. Int Arch Allergy Immunol 129:314-9. 76. Nakano, Y., M. Mori, S. Nishinohara, Y. Takita, S. Naito, A. Horino, H. Kato, M. Taneichi, Y. Ami, Y. Suzaki, K. Komuro, and T. Uchida. 1999. Antigen-specific, IgE-selective unresponsiveness induced by antigen-liposome conjugates. Comparison of four different conjugation methods for the coupling of antigen to liposome. Int Arch Allergy Immunol 120:199-208. 77. Nemeroff, M. E., X. Y. Qian, and R. M. Krug. 1995. The influenza virus NS1 protein forms multimers in vitro and in vivo. Virology 212:422-8. 78. Nemeroff, M. E., U. Utans, A. Kramer, and R. M. Krug. 1992. Identification of cis-acting intron and exon regions in influenza virus NS1 mRNA that inhibit splicing and cause the formation of aberrantly sedimenting presplicing complexes. Mol Cell Biol 12:962-70. 79. Neumann, G., T. Watanabe, and Y. Kawaoka. 2000. Plasmid-driven formation of influenza virus-like particles. J Virol 74:547-51. 80. Noton, S. L., E. Medcalf, D. Fisher, A. E. Mullin, D. Elton, and P. Digard. 2007. Identification of the domains of the influenza A virus M1 matrix protein required for NP binding, oligomerization and incorporation into virions. J Gen Virol 88:2280-90. 81. O''Neill, R. E., J. Talon, and P. Palese. 1998. The influenza virus NEP (NS2 protein) mediates the nuclear export of viral ribonucleoproteins. Embo J 17:288-96. 82. Odagiri, T., K. Tominaga, K. Tobita, and S. Ohta. 1994. An amino acid change in the non-structural NS2 protein of an influenza A virus mutant is responsible for the generation of defective interfering (DI) particles by amplifying DI RNAs and suppressing complementary RNA synthesis. J Gen Virol 75 ( Pt 1):43-53. 83. Okada, E., S. Sasaki, N. Ishii, I. Aoki, T. Yasuda, K. Nishioka, J. Fukushima, J. Miyazaki, B. Wahren, and K. Okuda. 1997. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J Immunol 159:3638-47. 84. Okamoto, T., Y. Kaneda, D. Yuzuki, S. K. Huang, D. D. Chi, and D. S. Hoon. 1997. Induction of antibody response to human tumor antigens by gene therapy using a fusigenic viral liposome vaccine. Gene Ther 4:969-76. 85. Olsen, C. W., M. W. McGregor, N. Dybdahl-Sissoko, B. R. Schram, K. M. Nelson, D. P. Lunn, M. D. Macklin, W. F. Swain, and V. S. Hinshaw. 1997. Immunogenicity and efficacy of baculovirus-expressed and DNA-based equine influenza virus hemagglutinin vaccines in mice. Vaccine 15:1149-56. 86. Panchal, R. G., G. Ruthel, T. A. Kenny, G. H. Kallstrom, D. Lane, S. S. Badie, L. Li, S. Bavari, and M. J. Aman. 2003. In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding. Proc Natl Acad Sci U S A 100:15936-41. 87. Phillips, N. C., L. Gagne, N. Ivanoff, and G. Riveau. 1996. Influence of phospholipid composition on antibody responses to liposome encapsulated protein and peptide antigens. Vaccine 14:898-904. 88. Pillay, S., A. Meyers, A. L. Williamson, and E. P. Rybicki. 2009. Optimization of chimeric HIV-1 virus-like particle production in a baculovirus-insect cell expression system. Biotechnol Prog 25:1153-60. 89. Possee, R. D. 1986. Cell-surface expression of influenza virus haemagglutinin in insect cells using a baculovirus vector. Virus Res 5:43-59. 90. Prel, A., G. Le Gall-Recule, and V. Jestin. 2008. Achievement of avian influenza virus-like particles that could be used as a subunit vaccine against low-pathogenic avian influenza strains in ducks. Avian Pathol 37:513-20. 91. Pushko, P., T. M. Tumpey, F. Bu, J. Knell, R. Robinson, and G. Smith. 2005. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 23:5751-9. 92. Qiu, Y., and R. M. Krug. 1994. The influenza virus NS1 protein is a poly(A)-binding protein that inhibits nuclear export of mRNAs containing poly(A). J Virol 68:2425-32. 93. Quan, F. S., C. Huang, R. W. Compans, and S. M. Kang. 2007. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 81:3514-24. 94. Quan, F. S., D. Steinhauer, C. Huang, T. M. Ross, R. W. Compans, and S. M. Kang. 2008. A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine 26:3352-61. 95. Rasmussen, L., J. K. Battles, W. H. Ennis, K. Nagashima, and M. A. Gonda. 1990. Characterization of virus-like particles produced by a recombinant baculovirus containing the gag gene of the bovine immunodeficiency-like virus. Virology 178:435-51. 96. Rhiel, M., C. M. Mitchell-Logean, and D. W. Murhammer. 1997. Comparison of Trichoplusia ni BTI-Tn-5B1-4 (high five) and Spodoptera frugiperda Sf-9 insect cell line metabolism in suspension cultures. Biotechnol Bioeng 55:909-20. 97. Rossman, J. S., X. Jing, G. P. Leser, V. Balannik, L. H. Pinto, and R. A. Lamb. Influenza virus m2 ion channel protein is necessary for filamentous virion formation. J Virol 84:5078-88. 98. Saelens, X., P. Vanlandschoot, W. Martinet, M. Maras, S. Neirynck, R. Contreras, W. Fiers, and W. M. Jou. 1999. Protection of mice against a lethal influenza virus challenge after immunization with yeast-derived secreted influenza virus hemagglutinin. Eur J Biochem 260:166-75. 99. Sakaue, G., T. Hiroi, Y. Nakagawa, K. Someya, K. Iwatani, Y. Sawa, H. Takahashi, M. Honda, J. Kunisawa, and H. Kiyono. 2003. HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses. J Immunol 170:495-502. 100. Sakoh, M., K. Ito, and Y. Akiyama. 2005. Proteolytic activity of HtpX, a membrane-bound and stress-controlled protease from Escherichia coli. J Biol Chem 280:33305-10. 101. Scheiffele, P., A. Rietveld, T. Wilk, and K. Simons. 1999. Influenza viruses select ordered lipid domains during budding from the plasma membrane. J Biol Chem 274:2038-44. 102. Simoes, S., J. N. Moreira, C. Fonseca, N. Duzgunes, and M. C. de Lima. 2004. On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev 56:947-65. 103. Singh, I., R. W. Doms, K. R. Wagner, and A. Helenius. 1990. Intracellular transport of soluble and membrane-bound glycoproteins: folding, assembly and secretion of anchor-free influenza hemagglutinin. Embo J 9:631-9. 104. Sinha, R. K., and G. K. Khuller. 1997. The protective efficacy of a liposomal encapsulated 30 kDa secretory protein of Mycobacterium tuberculosis H37Ra against tuberculosis in mice. Immunol Cell Biol 75:461-6. 105. Song, K. S., S. Li, T. Okamoto, L. A. Quilliam, M. Sargiacomo, and M. P. Lisanti. 1996. Co-purification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. Detergent-free purification of caveolae microdomains. J Biol Chem 271:9690-7. 106. Takeda, M., G. P. Leser, C. J. Russell, and R. A. Lamb. 2003. Influenza virus hemagglutinin concentrates in lipid raft microdomains for efficient viral fusion. Proc Natl Acad Sci U S A 100:14610-7. 107. Takizawa, N., M. Kumakura, K. Takeuchi, N. Kobayashi, and K. Nagata. Sorting of influenza A virus RNA genome segments after nuclear export. Virology 401:248-56. 108. Taneichi, M., H. Ishida, K. Kajino, K. Ogasawara, Y. Tanaka, M. Kasai, M. Mori, M. Nishida, H. Yamamura, J. Mizuguchi, and T. Uchida. 2006. Antigen chemically coupled to the surface of liposomes are cross-presented to CD8+ T cells and induce potent antitumor immunity. J Immunol 177:2324-30. 109. Tomita, N., R. Morishita, H. Y. Lan, K. Yamamoto, M. Hashizume, M. Notake, K. Toyosawa, B. Fujitani, W. Mu, D. J. Nikolic-Paterson, R. C. Atkins, Y. Kaneda, J. Higaki, and T. Ogihara. 2000. In vivo administration of a nuclear transcription factor-kappaB decoy suppresses experimental crescentic glomerulonephritis. J Am Soc Nephrol 11:1244-52. 110. Treanor, J. J., B. E. Wilkinson, F. Masseoud, J. Hu-Primmer, R. Battaglia, D. O''Brien, M. Wolff, G. Rabinovich, W. Blackwelder, and J. M. Katz. 2001. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19:1732-7. 111. Varma, R., and S. Mayor. 1998. GPI-anchored proteins are organized in submicron domains at the cell surface. Nature 394:798-801. 112. Venugopalan, P., S. Jain, S. Sankar, P. Singh, A. Rawat, and S. P. Vyas. 2002. pH-sensitive liposomes: mechanism of triggered release to drug and gene delivery prospects. Pharmazie 57:659-71. 113. Wang, B. Z., F. S. Quan, S. M. Kang, J. Bozja, I. Skountzou, and R. W. Compans. 2008. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol 82:11813-23. 114. Wang, J. X., X. Sun, and Z. R. Zhang. 2002. Enhanced brain targeting by synthesis of 3'',5''-dioctanoyl-5-fluoro-2''-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Pharm Biopharm 54:285-90. 115. Wang, K., K. M. Holtz, K. Anderson, R. Chubet, W. Mahmoud, and M. M. Cox. 2006. Expression and purification of an influenza hemagglutinin--one step closer to a recombinant protein-based influenza vaccine. Vaccine 24:2176-85. 116. Wen, Z., L. Ye, Y. Gao, L. Pan, K. Dong, Z. Bu, R. W. Compans, and C. Yang. 2009. Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge. Antiviral Res 84:215-24. 117. Yang, K., G. L. Clifton, and R. L. Hayes. 1997. Gene therapy for central nervous system injury: the use of cationic liposomes: an invited review. J Neurotrauma 14:281-97. 118. Yoshikawa, T., T. Uchida, S. Naito, A. Horino, M. Taneichi, H. Kato, K. Komuro, Y. Nakano, M. Mori, S. Nishinohara, J. Chiba, T. Kurata, and S. Tamura. 2000. Suppression of specific IgE antibody responses by liposome-conjugated ovalbumin in mice sensitized with ovalbumin via the respiratory tract. Int Arch Allergy Immunol 121:108-15. 119. Zhang, J., A. Pekosz, and R. A. Lamb. 2000. Influenza virus assembly and lipid raft microdomains: a role for the cytoplasmic tails of the spike glycoproteins. J Virol 74:4634-44. 120. Zolkiewski, M. 2006. A camel passes through the eye of a needle: protein unfolding activity of Clp ATPases. Mol Microbiol 61:1094-100.
自從高致病性流感病毒疫情在禽鳥之間爆發以來,對家禽養殖產業與大眾健康造成了重大威脅。為了避免流感病毒的感染,接種疫苗是最主要的預防措施。在許多預防病毒傳染性疾病所使用的疫苗類型中,似病毒顆粒具備安全與效果佳的優點,因其外在結構類似真實病毒顆粒且不含病毒基因體,因此被視為是可取代傳統流感疫苗。本研究為了探討流感似病毒顆粒形成的必需蛋白組成與其在雞隻中所引發的保護效果,遂將H7N1病毒的hemagglutinin (HA) 基因單獨構築、或與來自H6N1病毒之matrix 1 (M1) 基因或neuraminidase (NA) 基因共同構築表達。將所構築之3株重組桿狀病毒分別感染Hi-5細胞,證實所帶的流感病毒基因 HA、HA/M1或HA/NA/M1皆可表現,以20%~60%蔗糖梯度離心分析,發現單獨表達HA和共表現HA/M1和HA/NA/M1的樣品在密度1.10~1.16 g/cm3的區間都有很強的紅血球凝集反應,而在兩組共表現的梯度密度區間樣品則可同時偵測到M1或M1/NA,進一步以Sepharose CL-4B層析管柱純化,證實在上述的區間中含有大於2,000 kD的蛋白複體。上述結果顯示單獨HA就可以驅動budding的發生而形成只含有HA的似病毒顆粒。穿透式電子顯微鏡的觀察證實由HA或HA/M1或HA/NA/M1所組成的3種流感似病毒顆粒外型與真實流感病毒顆粒相似,皆具多型性,大小為80~150 nm。HA似病毒顆粒的發現為首次報導,此結果顯示HA蛋白為利用桿狀病毒表現系統生產流感似病毒顆粒所需的最小結構單元。雞隻免疫試驗的結果顯示含有2 μg HA抗原的VLPs於第一次注射後的二週內即可以令所有雞隻血清中的HI抗體力價成功達到16倍以上,第二次注射後,所有血清的HI力價明顯升高,並且持續至少三個月皆大於16倍。將VLP中的HA抗原含量降低至0.5或0.2 μg,單次注射最多僅有80% 雞隻血清呈現HI>16,而在第二次注射後的兩週內,HI>16的雞數達到100%。綜合以上的結果顯示,利用桿狀病毒表現系統生產流感似病毒顆粒具有開發成為安全且有效的流感疫苗的潛力,更重要的是,本研究中所報導的單單HA-VLPs流感疫苗就可提供一個簡單且快速的生產。

Outbreaks of highly pathogenic influenza viruses in avian species have resulted in great impacts on poultry industry and especially on public health. Influenza virus-like particles (VLPs) have been suggested to be a promising vaccine approach because of their safety and effectiveness in vaccination. For improving the production of VLP-based influenza vaccines, Hemagglutinin (HA) gene alone and in combination with matrix 1 (M1) or M1/ neuraminidase (NA) genes were constructed in baculovirus vectors for the expression of pertinent membrane proteins of these viruses. HA, HA/M1 or HA/NA/M1 proteins expressed and clarified by sucrose gradient ultracentrifugation produced strong hemagglutination responses in the fractions with sucrose densities between 1.10 and 1.16 g/cm3. Further purification by Sepharose CL-4B column demonstrated that these fractions contained proteins with an expected size larger than 2000 kDa. These results suggest that VLPs were formed and released into culture medium when HA was either individually expressed or co-expressed with M1 or with NA/M1. Transmission electron microscopy analysis showed that these VLPs with a diameter of 80-150 nm were pleiomorphic and similar to the authentic influenza virions. VLPs consisting of HA alone observed herein for the first time suggests that HA protein was the minimal protein requirement for the production of influenza VLPs using baculovirus expression system. With sera collected from 2 μg VLP (based on the HA contents)-vaccinated chickens two weeks after the prime injection, the hemagglutination inhibition titers induced by these three kinds of VLPs were found to be higher than 16. The titers were promoted after the boost injection and persisted for at least three months higher than 16. These results indicate that using insect cells to harvest the recombinant influenza VLPs may be a promising approach for the development of a safe and effective vaccine against the influenza virus infection. Most of all, VLPs consisting of HA only provides a simple and fast technical platform for annual influenza virus vaccine manufacturing.
其他識別: U0005-1511201016371900
Appears in Collections:生物科技學研究所

Show full item record

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.